Optimization of oral entacapone administration in patients undergoing levodopa–carbidopa intestinal gel treatment

Levodopa–carbidopa intestinal gel (LCIG) treatment markedly reduces motor fluctuations in patients with Parkinson's disease; however, some patients undergoing LCIG treatment may demonstrate clinical deterioration in the afternoon. Entacapone, a catechol-O-methyltransferase inhibitor, may be a p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the neurological sciences 2024-02, Vol.457, p.122901-122901, Article 122901
Hauptverfasser:	Miyaue, Noriyuki, Ito, Yuko, Yamanishi, Yuki, Tada, Satoshi, Ando, Rina, Yabe, Hayato, Nagai, Masahiro
Format:	Artikel
Sprache:	eng
Schlagworte:	3–O–methyldopa Entacapone Levodopa pharmacokinetics Levodopa–carbidopa intestinal gel Parkinson's disease
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!